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• We conducted a retrospective analysis of post epilepsy surgery outcomes from 3 30 
different data sources: case notes, patient questionnaires and a national 31 
anonymized linked health and population databank    32 
• 49% of patients were seizure free at last follow up (median follow up of 7 years) 33 
with 88% having at least a worthwhile improvement in seizure frequency 34 
following resective epilepsy surgery 35 
• There was a significant increase in quality of life (QOLIE-31-P) 36 
• There was a significant reduction for all cause hospital admissions post-surgery 37 







Objective: To assess the long-term outcomes of epilepsy surgery between 1995–2015 in 43 
South Wales, UK, linking case note review, postal questionnaire and routinely-collected 44 
healthcare data. 45 
Method: We identified patients from a departmental database and collected outcome data 46 
from patient case notes, a postal questionnaire and the QOLIE-31-P and linked with Welsh 47 
routinely-collected data in the Secure Anonymised Information Linkage (SAIL) databank. 48 
Results: 57 patients were included. Median age at surgery was 34 years (11–70); median 24 49 
years (2–56) after onset of habitual seizures. Median follow-up was 7 years (2–19). 28 (49%) 50 
patients were free from disabling seizures (Engel Class 1), 9 (16%) experienced rare 51 
disabling seizures (Class 2), 13 (23%) had worthwhile improvements (Class 3) and 7 (12%) 52 
no improvement (Class 4). There was a 30% mean reduction in total anti-epileptic drug 53 
(AED) load at five years post-surgery. 38 (66.7%) patients experienced tonic-clonic seizures 54 
pre-surgery verses 8 (14%) at last review. Seizure-free patients self-reported a greater overall 55 
quality-of-life (QOLIE-31-P) when compared to those not achieving seizure freedom. 56 
Seizure-free individuals scored a mean of 67.6/100 (100 is best), whereas those with 57 
continuing seizures scored 46.0/100 (p<0.006). There was a significant decrease in the 58 
median rate of hospital admissions for any cause after epilepsy surgery (9.8 days per 1000 59 
patient days before surgery compared with 3.9 after p<0.005). 60 
Significance: Epilepsy surgery was associated with significant improvements in seizures, a 61 
reduced AED load and an improved quality-of-life that closely correlated with seizure 62 
outcomes and reduced hospital admission rates following surgery. Despite this there was a 63 
long delay from onset of habitual seizures to surgery. The importance of long-term follow-up 64 





AEDs, Anti-epileptic drugs; DRE, Drug resistant epilepsy; HS, Hippocampal sclerosis; 68 
IGRP, Information Governance Review Panel; QOL, Quality of life; SAIL, Secure 69 
Anonymous Information Linkage; VNS, Vagus nerve stimulator. 70 
 71 
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1 Introduction: 76 
Epilepsy is a chronic condition with a prevalence of 50 million worldwide and an incidence 77 
of 2.4 million per annum (1). In Wales, approximately 30,000 people suffer with epilepsy (2). 78 
The main treatment of epilepsy is pharmacological intervention with anti-epileptic drugs 79 
(AEDs). However, a third to a half of patients develop seizures that are resistant to AEDs, 80 
referred to as drug resistant epilepsy (DRE) (3). DRE is commonly defined as a failure to 81 
achieve sustained seizure freedom after treatment with at least two appropriately chosen and 82 
appropriately used AEDs, in monotherapy or in combination (4-6). The reasons why DRE 83 
develops remains unknown (7). Delineation and surgical resection of epileptogenic brain 84 
tissue is a treatment option with a strong evidence base for reducing or halting seizures 85 
and reducing AED dependence, along with beneficial outcomes on quality of life (QOL) 86 
in appropriately selected and evaluated cases (8-12).   87 
Delay from onset of habitual seizures and drug resistance to surgical treatment is well 88 
recognized with intervals of several decades in most case series (11-14). One reason for this 89 
delay may be poor knowledge of the available surgical options, and perception of patients, 90 
carers and treating physicians.  The time to surgery probably impacts on morbidity and 91 
mortality (15), and those not proceeding to surgery have been found to be 2.4 times more 92 
likely to die than those who did have surgery (16). Life expectancy itself has also been shown 93 
to be on average five years longer in operated drug resistant epilepsy compared to those 94 
remaining on medical therapy (17). 95 
A small number of studies have looked at epilepsy surgery outcomes beyond five years (18-96 
23) with many others only reporting outcomes at three years or less (9, 10, 13). An important 97 
outcome, in addition to seizure freedom, is change in AED treatment load post-surgery; one 98 
review of outcome studies with more than five years follow up found that less than a quarter 99 
of studies included outcomes on AED changes and patient QOL measures (21).  100 
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We therefore set out to study the long-term outcomes of epilepsy surgery at our center, that 101 
serves a relatively stable population in South Wales, UK. We focused on seizure outcome 102 
measures, quality of life, AED use and hospital admissions rates. We aimed to access three 103 
separate sources of information for our outcome measures: 1) the patients’ clinical 104 
records, 2) a postal questionnaire including the QOLIE-P31, 3) a national secure 105 
database of anonymized health and social care records.    106 
2 Methods 107 
Approval for the study was given by the hospital Continuous Service Improvement Office, 108 
Cardiff and Vale University Health Board, Wales, UK. We identified 84 patients from the 109 
epilepsy unit departmental database who had undergone resective epilepsy surgery between 110 
1995 and 2015. We did not include patients where the primary aim of surgery was tumor 111 
resection or those undergoing vagus nerve stimulator (VNS) implantation. We obtained 112 
information for 84 patients by reviewing paper case notes and the hospital’s online clinical 113 
records portal [electronic front end for clinical investigations, attendances and letters (from 114 
2008)]. All patients had undergone evaluation with video-EEG telemetry, MRI and pre-115 
operative psychological assessments. Patients operated before 2011 were evaluated with 116 
video-EEG telemetry at Kings College Hospital, London, and thereafter all evaluations were 117 
undertaken in Cardiff. Patients were operated by one of 2 neurosurgeons [RH (pre-2012) and 118 
WG (post-2012)].   119 
 Patient hospital records 120 
From the patient’s hospital records we determined changes in seizure frequency and 121 
character, time to surgery from initial diagnosis, changes in AEDs and any record of adverse 122 
surgical events or psychiatric, cognitive and visual problems (pre-surgical baselines were 123 
noted).  We used Engel classification to determine seizure outcome at the most recent out-124 
  
 8 
patient appointment, where one is the best outcome and four the worst, with subcategories for 125 
each class (appendix 1 – supplementary materials). This has good agreement with the ILAE 126 
outcome scale (24) but maintains subcategories for seizure type e.g., focal versus bilateral 127 
tonic clonic. 128 
 Questionnaire and QOLIE-31-P 129 
A questionnaire was developed to identify the patient’s current perspective on having 130 
experienced epilepsy surgery including their report of seizure frequency (daily, weekly, 131 
monthly, yearly and none in the past year), employment and driving status (appendix 2 – 132 
supplementary materials). We also included the QOLIE-31-P which was originally developed 133 
by Crammer to specifically assess the quality of life of people with epilepsy (25). The 134 
QOLIE-31-P takes into account the patients’ perception of: levels of energy, emotional toll, 135 
daily activities, mental activity, medication effects, seizure attitudes and their feelings on 136 
quality of life overall (appendix 3 – supplementary materials).  Responses to the QOLIE-31-P 137 
were scored according to standard instructions giving an overall score for each patient 138 
ranging from 1–100 (100 being the best QOL) (25). Given the large number, type and doses 139 
of AEDs to be assessed at different time points over a period of up to 20 years, comparison 140 
over time can be difficult. We therefore developed a system to calculate a drug load or 141 
burden with respect to the maximum recommended daily dose, as well as recording the total 142 
number of AEDs. For each AED, we calculated a ratio of total daily dose taken compared to 143 
the maximum recommended daily dose [from British National Formulary, March 2017(26)]. 144 
Thus, a patient taking the maximum recommended daily dose would score 1, a patient taking 145 
50% of daily dose 0.5, and so forth. For example, a patient taking levetiracetam 1250mg BD 146 
would score 2500/3000=0.83 (3000mg being the highest recommended daily dose (26)). 147 
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 Anonymised linked heath care records 148 
We used the Secure Anonymous Information Linkage databank (SAIL) (Health Data 149 
Research UK, Swansea University) to anonymously link the list of patients having had 150 
resective epilepsy surgery to routinely-collected primary care and hospital admission records 151 
(27, 28).  We included patients who were registered as living in Wales during the periods five 152 
years before and after the epilepsy surgery. We recorded the length of stay for all hospital 153 
admissions and total time registered as living in Wales before and after surgery excluding one 154 
month immediately before and after surgery to exclude specific peri-operative related 155 
hospital stays. We compared the rates of admission before and after surgery using a signed 156 
Wilcoxon Signed-Rank test.  157 
All studies using SAIL data need independent Information Governance Review Panel (IGRP) 158 
approval but do not require specific NHS research ethics committee approval. This study 159 
obtained IGRP approval ref 0565. 160 
3 Results 161 
We identified 406 cases as having epilepsy and neurosurgery in our department, from which 162 
84 were identified as having resective epilepsy surgery. 64 sets of case notes were available 163 
for review. We excluded a further seven cases [three had palliative not resective procedures, 164 
two insufficient case notes, and two did not have neurosurgery (incorrectly identified)], 165 
leaving a total of 57 patients for patient note review.  166 
 Results of hospital record review  167 
Of the 57 patients forty-nine were right handed, seven left and one ambidextrous. 51% (29) 168 
of patients had a history of febrile seizures, 47% were noted to have not suffered a febrile 169 
seizure and one was undocumented. Patients had a median age at surgery of 34, with the 170 
median time between onset of habitual seizures and surgery being 24 years (range 2–171 
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56). It would be important to record the time interval from consideration of epilepsy 172 
surgery to the surgery itself. However, we did not have access to these data. As a proxy, 173 
we recorded the date of video telemetry in 36 cases, there was a median interval of 12 174 
months (range 6-36) between video-telemetry and surgery. 175 
 176 
Median duration of outpatient follow up after surgery was seven years (range 1–19). All 57 177 
patients had 1 year of follow up, with 40 still being followed up at 5 years, 25 at 7-8 178 
years, 22 at 10 years, 13 at 12-13 years and 3 at greater than 15 years.  Lateralization and 179 
histopathological diagnoses are shown in figure 1. We found a significant difference in the 180 
number of patients operated with left (n=28) and right (n=14) hippocampal sclerosis (HS) 181 
p<0.02 (one sample binomial test). 182 
The type of surgery is summarized in table 1. 183 
 184 
Type of Surgery Number of patients 
Anterior temporal lobectomy 40 (27 left, 13 right) 
Selective amygdalohippocampectomy 7 (5 left, 2 right) 
Lesionectomy  10.  
Temporal, n=4: Epidermoid x2, DNET x2  
Frontal, n=4: Ganglioglioma, Epidermoid, 
cortical dysplasia x2  
Parietal, n=1: DNET  
Occipital,  n=1: Ganglioglioma  
 185 
Table 1: Type of surgical procedure undertaken. DNET; Dysembryoplastic Neuroepithelial 186 
Tumor 187 
  188 
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3.1.1 Post-operative seizure outcomes 189 
49% (28) of patients were at Engel class 1 (free from disabling seizures), 16%(9) class 2, 190 
23%(13) class 3 and 12%(7) at class 4 (no worthwhile improvement) (figure 2a) at last follow 191 
up (median 7-years). Figure 2b demonstrates the change in time of Engle class of those 192 
patients who were followed up at 1, 5, and 7-8 years (N= 57, 40, 25 respectively)  A more 193 
detailed breakdown of seizure type and frequency before and at one year following surgery 194 
was also determined (figure 2c), and of seizure type and frequency at long term follow up 195 
(figure 2d).  196 
3.1.2 Post-operative morbidity outcomes 197 
10.5% (6) patients suffered surgical site infections with three requiring cranioplasty and 198 
one requiring an intensive treatment unit (ITU) admission. Three patients experienced 199 
psychiatric events post-surgery that required inpatient stays.  One of these required 200 
involuntary detention under the mental health act after attempting suicide by violent means. 201 
40% (23) patients experienced at least partial upper quadrantanopia visual impairment 202 
on formal testing. 203 
3.1.3 Anti-epileptic drug usage  204 
Patient follow up data reduced with increasing time post-surgery, and therefore, total drug 205 
consumption was calculated per capita (Figure 3). The mean number of AEDs pre-surgery 206 
was 2.35, at last clinic appointment this figure had dropped to 1.83, a reduction of 22%. Of 207 
the 20 patients who stopped AEDs entirely, only three remained seizure free with the 208 
remaining 17 restarting AED treatment for seizure recurrence.  Of the three seizure-free 209 
patients, two stopped their AEDs, both stopped medication one year post-surgery and had 210 
follow up at three and five years post operatively. The third patient attempted to come off 211 
medication at four years but unfortunately relapsed on this attempt and restarted 212 
carbamazepine. However, after a second attempt at medication withdrawal they 213 
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remained seizure free at follow up, 13 years after surgery. Of the remaining 54 patients, 214 
33 (61%) were on a reduced total AED load compared to pre-surgery, 13 were on the 215 
same and eight were on a greater AED load.  216 
 Results of postal questionnaire    217 
Of the 84 patients identified, 34 (40%) returned postal questionnaire and QOLIE-P31 218 
forms, all completing both questionnaire and QOLIE-P31. Four responses to the QOLIE-219 
P31 were excluded due to incomplete responses to the questions obviating score calculations. 220 
Results of the questionnaire are summarized in table 2. 221 
Table 2: Questionnaire responses for employment, driving and seizure status. 222 
 223 
The seven patients who returned to drive did so at a mean of 3.5 years post-surgery. 224 
Patients’ questionnaire responses to seizure frequency can be seen in figure 2d.  Two patients 225 
(6%) experienced no reduction in seizure frequency, with the rest experiencing at least a one 226 
class reduction. 13 (40%) patients reported seizure freedom. No patients reported worsening 227 
seizures however, 3 patients reported that their QOL had decreased. 26 (76%) of the 34 228 
patients reported that their QOL has improved to some extent (Figure 5). 229 
  QOLIE-P31 questionnaire 230 
Scores were calculated from the 30 complete responses. The final score is a scale ranging 231 
from 0–100, with a score of 100 being the best possible QOL. The mean score was 55.2 (s.d. 232 
21.7). Those free of seizures scored a mean of 67.9 whereas those who did not achieve 233 
 Yes No 
Employment (Full or part time) 12 22 
Driving 7 27 
Seizure free  21 13 
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seizure freedom scored 46.1, a difference of 21.6 (95% CI 7.0,37.9) p<0.006 (Mann-Whitney 234 
U).  235 
 Results of anonymized healthcare data 236 
We were able to link 34 patients with routinely-collected healthcare data before and after 237 
surgery.  The proportion of men, mean age at diagnosis and age at surgery were 38%, 10 238 
years and 36 years respectively in this sub-group.  239 
There was a significant decrease in the median rate of hospital admissions for any cause 240 
when comparing the five years after surgery with the five years immediately prior to surgery 241 
(3.89 days per 1,000 patient days after surgery compared with 9.84 days per 1,000 days 242 





4.1 Discussion 246 
We conducted an evaluation of long-term outcomes in patients having undergone epilepsy 247 
surgery in Cardiff, UK. We found that 49% of patients were free of disabling seizures (Engel 248 
class 1) at their most recent outpatient visit, a median of seven years post-surgery (Range 2–249 
19). Our seizure outcome findings are similar to those reported by others five years post-250 
surgery, (18-23).  The majority of patients were taking fewer AEDs following surgery. 251 
QOLIE-P31 scores were significantly higher in those who achieved seizure freedom 252 
compared to those who did not. There was close correlation between seizure outcomes, 253 
subjective quality of life questionnaire responses and QOLIE-P31 scores in the postal 254 
questionnaire/QOLIE-P31 cohort. The majority of patients responding to the questionnaire 255 
reported a positive outcome after epilepsy surgery, even if not seizure free post-surgery. We 256 
found a measurable reduction in total AED dosing following surgery, using a metric of ‘AED 257 
load’, along with the total number of AEDs taken per person. We were able to link 34 of the 258 
patients (60% of cohort) with 5 years of routinely-collected anonymized healthcare data 259 
before and after surgery that showed a significant reduction in all hospital stays after surgery 260 
for this cohort. 261 
We found significantly more left HS resections when compared to right HS resections in our 262 
series. This has also been reported by other centers. (29) The reasons are unclear, and we do 263 
not know the overall prevalence of all HS in our epilepsy population, though a higher 264 
prevalence of left compared to right HS has been reported by others (30, 31). We postulate 265 
that left HS could have been more likely to come to surgery because of more debilitating 266 
seizures (with loss of awareness), compared to right HS (32), or more likely to be present or 267 
be under follow at tertiary centers for the same reason.  268 
Previous studies have reported AED use and seizure freedom (21, 33), we found it 269 
additionally helpful to develop a measure of AED burden as an outcome measure.  270 
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This showed a 30% reduction in drug dosage five years post-surgery in comparison to pre-271 
surgery. Previous literature has drawn associations with the AEDs themselves reducing QOL 272 
(34) and AED cessation improving cognition (35). In our cohort 20 of the 57 patients had a 273 
trial of complete AED withdrawal, and of those, only three remained seizure free and off 274 
AEDs, this may reflect local practice of reducing to low dose single AED in preference to 275 
recommending complete withdrawal, the latter generally occurring only in patients who were 276 
seizure free and requesting to stop all AEDs. 277 
Patients’ subjective interpretation of their health seems to correlate with their clinical picture, 278 
with 14.7% reporting no change or a decrease in their QOL on their questionnaire responses 279 
with a similar percentage as those who class as Engel IV (Figure 2a). Although, these were 280 
not necessary the same individuals, as responses and case notes could not be linked due to 281 
questionnaires being anonymized at the start of data collection. Those completely seizure free 282 
reported a significant difference in their QOLIE-P31 compared to those not seizure free 283 
(P<0.006). Of the 19 patients who returned their questionnaire who were still experiencing 284 
seizures, 12 still described their QOL ‘much improved’ or ‘very much improved’ following 285 
surgery, demonstrating the importance of recording patient’s opinions and QOL measures in 286 
addition to Engel scores.    287 
Although a majority of patients reported an increase in QOL post-surgery, many 288 
burdens of their chronic disease including higher cognitive functioning persist. This 289 
may explain why our patients’ employment levels post-surgery remain low. Of the 38 290 
patients in whom we had records for both pre and post-surgery neuropsychometry 291 
testing, only 13% (5) had mild improvements to verbal memory. A majority showed 292 
similar performance or a mild reduction in verbal memory compared to pre-surgery 293 
testing. Age at surgery and duration of epilepsy are also likely factors in predicting 294 
post-operative employment.  Career prospects have been shown to be optimal when 295 
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surgery is performed at a young age with minimal time between habitual seizure and 296 
referral (36). The median time of 24 years to surgery in our cohort was a likely factor in 297 
low rates of employment after surgery even if seizure free. 298 
 299 
Despite nearly 50% of our cohort being seizure free at their most recent outpatient 300 
appointment, only 21% (7) were driving based on questionnaire responses. A previous 301 
systematic review found wide variation in driving status post-surgery (7-65%), age at 302 
surgery was a factor (37). National variation in transport links also likely contributes. 303 
 304 
Previous studies have noted a wide range of visual field defects (VFD) (6-76%) following 305 
temporal lobectomy or selective mesial resection. One report found that of the nearly 306 
75% who experienced VFD,  48% had driving-relevant VFD (38, 39). 40% of our total 307 
cohort were documented as having post-surgical VFD although the extent of the deficit 308 
and impact on driving was not recorded. Questionnaires responses suggested ongoing 309 
anxiety associated with driving. Many spent decades adapting their life to manage 310 
without the need for driving and there was a sentiment of not wanting to ‘tempt fate’.    311 
 312 
The goal of epilepsy surgery is to achieve long-term seizure freedom. The achievement 313 
of seizure freedom is not a static event. Previous studies have found a correlation 314 
between long term seizure freedom and absence of focal seizures with retained 315 
awareness in the first 2 post-operative years (12)(40).  In our cohort, eight patients who 316 
were seizure free at one-year post-surgery experienced seizures in some capacity at five 317 
years post-surgery. Our measure of AED load showed a continued fall until at least 318 
eight years post-surgery. Had our follow up period been shorter, cases of relapse would 319 
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have remained unrecorded, and the extent of reduced AEDs would also have been 320 
missed, emphasizing the need for longer term follow up.  321 
 322 
Given the benefits of timely epilepsy surgery, it is important to highlight the need to 323 
reduce the time taken to refer to epilepsy surgery. The reasons for delay are likely a 324 
combination of the need for better information amongst the neurology community and 325 
adequate resources.  One study of 796 neurologists found over half would wait a year 326 
before a surgical referral in those suffering from refractory epilepsy, over 75% felt the 327 
greatest barrier was a lack of resources (41).  Furthermore, the time to surgery after 328 
initial pre-surgical evaluation is important and steps in the surgery pathway need to be 329 
streamlined as far as possible.  330 
 331 
Linking our surgical cohort to the SAIL database of routinely-collected health care data 332 
showed a clear reduction in hospital admissions as a marker of health care utilization post-333 
surgery. This represents an additional cost saving when coupled with the reduction in AED 334 
costs. 335 
Our study had limitations, mainly the retrospective data collection and the incomplete data 336 
capture. This could have introduced bias, e.g., unavailable clinical notes in those lost to 337 
follow-up, who perhaps had better seizure outcomes, subjective interpretation during clinical 338 
assessments, and those who returned questionnaires, with only a 40% response rate being 339 
biased toward those reporting improved (or otherwise QOL), or biased by their experience of 340 
epilepsy surgery.  Trying to ascertain why some in our cohort failed to achieve seizure 341 
freedom is limited by sample size and retrospective review. Trying to establish causality as to 342 
which pre-surgical factors could be a marker to surgical failure remains challenging. We 343 
were also only able to link 60% of the patients with 10 years of their routinely-collected data 344 
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mostly due to incomplete historic data and lack of linkage due to changes of addresses 345 
outside Wales. Nevertheless, we show significant changes in the factors we were able to 346 
measure and demonstrate this as a way forward for future studies of post-operative epilepsy 347 
surgery outcomes. Finally, our cohort predominantly consisted of lesional temporal 348 
epilepsy cases with hippocampal sclerosis and those with other cortically based lesions. 349 
It is known that best surgical outcomes are seen in lesional temporal lobe cases and 350 
future studies are needed to address outcomes from more complex epilepsy surgical 351 
procedures (42).  352 
 353 
 354 
5.1 Conclusion 355 
In summary, we demonstrate the demographics and benefits of epilepsy surgery in terms of 356 
seizure outcomes, quality of life and health care utilization. We, as elsewhere, note a long 357 
delay from diagnosis to surgery, and continued work is needed to improve this, in addition to 358 
continued monitoring of long-term outcomes after epilepsy surgery.  359 
 360 
 361 
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Table and figure legends 478 
 479 
Figure 1.  The histological causes of the epilepsy in our cohort of 57 patients. 480 
 481 
Figure 2. a). Post-operative outcomes at most recent outpatient clinic (median follow up 7 482 
years) - Engel classification. (see appendix 1). b) Engle classification of patients at 1, 5 and 483 
7-8 years after their surgery. c) The type and frequency of seizures, pre-surgery and one year 484 
after surgery. d) Type and frequency of seizures, against patient number and percentage at 485 
their last outpatient clinic.     486 
 487 
Figure 3. Drug use per capita in the years following surgery. The number on the Y axis refers 488 
to the average anti-epileptic drug score per capita. AEDs were scaled, where 1 is the 489 
maximum dose of single drug as recommended by the British National formulary (March 490 
2017). Patients scores were added together to give an overall number and per capita 491 
calculated. 492 
 493 
Figure 4. Subjective QOL questionnaire responses ranging from one to 13 years post-494 
surgery.  495 
 496 
Figure 5. Box and whisker plot showing the difference in quality of life of those who 497 
achieved seizure freedom following surgery and those who did not.     498 
 499 
Figure 6. Box and whisker plot of admission rates per 1,000 days for the five years before 500 
and after surgery. The median hospital admission rates were 9.84 per 1,000 patient days 501 
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This study makes use of anonymised data held in the Secure Anonymised Information 565 
Linkage (SAIL) system. We would like to acknowledge all the data providers who make 566 
anonymised data available for research. We thank our patients for their participation in 567 
the survey and support from the Wales Epilepsy Unit.  568 
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Appendix 1: Engel classification score.  569 
Class I. Free from disabling seizures 
A. Completely seizure free since surgery  
B. Non disabling simple partial seizures only since surgery  
C. Some disabling seizures after surgery, but free from disabling seizures for ≥2 years  
D. Generalized convulsions w/AED discontinuation only  
 570 
Class II. Rare disabling seizures (almost seizure free) 
A. Initially free from disabling seizures, but still has rare seizures 
B. Rare disabling seizures since surgery 
C. Occasional disabling seizures since surgery, but rare seizures for the last 2 years 
D. Nocturnal seizures only 
 
 571 
Class III. Worthwhile improvement 
A. Worthwhile seizure reduction 
B. Prolonged seizure-free intervals amounting to >50% of follow-up period, but not <2 
years 
 572 
Class IV. No worthwhile improvement 
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A. Significant seizure reduction 
B. No appreciable change 
 
C. Seizures worse 
  573 
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Appendix 2: Patient questionnaire: 
 
Service Evaluation of Epilepsy Surgery in Wales  
  
                                   Patient Questionnaire  
 
We would be grateful if you could take a couple of minutes to answer this 
questionnaire. Your answers will help us evaluate and improve the current services 
available to people with epilepsy in Wales.   
  
Please tell us your full name, date of birth and address:  
  































Epileptic Seizures  
  
How frequent were your seizures before surgery?  
  
• Every month  
• Every week  
• Every day  
  
 33 
• Once or twice a year  
  
Please tell us what kind of seizures these were:  
  
……………………………………………………………………………………  
   
How frequent were your seizures in the first year after surgery?  
• Every month  
• Every week  
• Every day  
• Once or twice a year  
• Never  
  
Please tell us what kind of seizures these were:  
  
……………………………………………………………………………………  
   
How frequent have your seizures been in the last year?  
  
• Every month  
• Every week  
• Every day  
• Once or twice a year  




If ‘never’, please tell us when was the last time you had a seizure and describe 
what kind of seizure you had:   
  
……………………………………………………………………………  
   
Antiepileptic Medication  
  
If you can, please tell us the number and names of the medications you were taking for 
your epilepsy in the year before surgery:  
  
……………………………………………………………………………………   
  
If you can, please tell us the number and names of the medications you were taking for 
your epilepsy in the year after surgery:  
  
……………………………………………………………………………………  
   









   
Driving  
  
Do you currently drive?  
• Yes  
• No  
  
If you answered ‘yes’ to the previous question or have previously driven, please 






What is your current employment status?  
  
• Full-time employment  
• Part-time employment  
• Unemployed  
• In higher education  
  





   
Global Impression of Change and Quality of Life  
  
Over the past year, how have you felt compared to before you had surgery for your 
epilepsy? (please tick the box that best describes your condition):  
  
• Very much improved  
• Much improved  
• Minimally improved  
• No change  
• Minimally worse  
• Much worse  
• Very much worse  
  
How has the quality of your life changed since you had surgery for your epilepsy?  
  
• Very much improved  
• Much improved  
• Minimally improved  
• No change  
• Minimally worse  
• Much worse  




Is there anything else you would like to tell us?  
  
……………………………………………………………………………  
   
If you are happy for your comments to be included (anonymously) in any publication, 
please indicate so here:  
  
• I am happy for my comments to be used in any publication  
  
• I do want my comments to be used in any final publication  
  
             Are you happy for us to contact you by telephone if further information is 
required?   
     
• Yes  
• No  
  










Thank you for taking the time to answer and return this questionnaire. We would 
appreciate if you could also answer the ‘Quality of Life in Epilepsy’ 
questionnaire. Your responses will be anonymised and will help us to review 
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